Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Studies have shown that microRNAs (miRNAs) in red blood cells (RBCs) contribute most of the miRNAs in whole blood, and miRNAs in RBCs are closely related to storage lesions in vitro. However, the role of miRNAs in the process of RBC senescence in vivo remains unclear. We conducted a comprehensive miRNA expression analysis of RBCs collected from enriched mature RBCs in five density layers. The results showed that the type and number of RBC miRNAs changed with the aging of RBCs, the expression levels of 10 RBC miRNAs decreased markedly at the early stage of RBC aging and the levels of 5 RBC miRNAs increased significantly at the terminal stage of RBC senescence. The analysis identified 32 miRNAs whose changes in expression levels were correlated with the two selected aging indexes-pyruvate kinase (PK) activity and RBC indices. The differential expression amounts of the two selected miRNAs (miR-22-3p and miR-144-3p) were confirmed by real-time polymerase chain reaction (PCR) analysis. A bioinformatics analysis identified the potential targets and biological functions of these miRNAs. The experiment of miR-22-3p in the human erythroblast cell line K562 confirmed its negative effects on PK levels. Overall, our research demonstrates, for the first time, that changes in the expression levels of miRNAs during the RBC aging process, and RBC miRNAs thus have the potential to serve as markers of RBC aging in vivo. In addition, the expression of miR-22-3p may regulate RBC senescence by inhibiting PK levels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918798PMC
http://dx.doi.org/10.1097/BS9.0000000000000209DOI Listing

Publication Analysis

Top Keywords

rbc mirnas
16
mirnas
12
rbc senescence
12
expression levels
12
rbc aging
12
rbc
11
aging process
8
process rbc
8
levels rbc
8
stage rbc
8

Similar Publications

In vitro red blood cell (RBC) production offers a promising complement to conventional blood donation, particularly for patients with rare blood types. Previously, we developed imBMEP-A, the first erythroid cell line derived from reticulocyte progenitors, which maintains robust hemoglobin expression and erythroid differentiation in the presence of erythropoietin (EPO) despite its immortalized state. However, clinical translation remains hindered by the inability to scale up production due to impaired in vitro enucleation of RBC progenitor cell lines.

View Article and Find Full Text PDF

Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. Recently, it was discovered that microRNAs (miRNAs), which circulate freely in the circulation or biofluids, have diagnostic or prognostic potential. The current study looked at the levels of expression of three miRNAs in the serum and follicular fluid (FF) of PCOS patients and healthy women.

View Article and Find Full Text PDF

Thalassemia is one of the most prevalent genetic disorders. Blood transfusion, as the main treatment, harbors diverse side effects, including alloimmunization to RBC antigens, exacerbating hemolysis, and blood requirements. The role of miR155, as a regulator of the immune system, was investigated to divulge its role in the production of alloantibodies in thalassemia patients.

View Article and Find Full Text PDF

Breast cancer (BC) remains the leading cause of cancer-related morbidity and mortality worldwide, necessitating innovative approaches to improve diagnosis, prognosis, and treatment. This case-control study, aimed to evaluate the expression profiles of specific microRNAs (miRNAs)-miR-155-5p, miR-21-5p, miR-93-5p, and miR-140-5p-in 50 female BC patients treated with paclitaxel (PTX) compared to 50 healthy controls. miRNA expression was analyzed using qPCR.

View Article and Find Full Text PDF

Objective: The high morbidity and mortality of liver diseases warrant the development of more effective therapeutic methods. Extracellular vesicles (EVs) are optimal drug delivery vehicles, albeit with insufficient targeting specificity. The aim of this study was to develop modified red blood cell-derived EVs (RBC-EVs) for targeted drug delivery into hepatocytes, and verify their therapeutic efficacy in animal models of acute liver failure (ALF), non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF